Meloxicam/rizatriptan
Meloxicam/rizatriptan, sold under the brand name Symbravo, is a fixed-dose combination medication used for the treatment of migraine. It is a combination of meloxicam, a nonsteroidal anti-inflammatory medication; and rizatriptan, a serotonin 1B/1D receptor agonist. It is taken by mouth.
Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.